Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and
0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the
treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex
(TSC).